Highlights AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.92 ^USD	-2.97%		+1.82%	-31.35%

May. 07	Transcript : AbCellera Biologics Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07	AbCellera Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AbCellera Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Posts Q1 Revenue $10M, vs. Street Est of $10.9M	May. 07	MT
AbCellera Biologics Inc., Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies	May. 01	CI
AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases	Mar. 11	MT
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions	Mar. 11	CI
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024	Mar. 05	CI
AbCellera Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Reports Fiscal 2023 Revenue $38M	Feb. 20	MT
Abcellera Biologics, Inc. Announces Reorganization	Nov. 28	CI
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023	Nov. 03	CI
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Posts Q3 Revenue $6.6M, vs. Street Est of $11.5M	Nov. 02	MT
AbCellera Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
AbCellera Biologics Inc. Expands Multi-Target Antibody Discovery Collaboration with Regeneron	23-09-20	CI
AbCellera and Incyte to Collaborate on Therapeutic Antibody Development in Oncology	23-09-13	MT
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology	23-09-13	CI
AbCellera Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Posts Q2 Revenue $45.9M, vs. Street Est of $12.2M	23-08-03	MT
AbCellera Biologics Says Rehearing Request Against Microfluidic Devices Patent Denied	23-07-25	MT
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera	23-06-15	CI
AbCellera Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Highlights

Filters